Helixgate

Helixgate

Fierce Biotech

Oryon shines out of stealth with $21M to fight Parkinson’s disease

Published

on

When Ron Cohen, M.D., CEO of Oryon Cell Therapies, recently dug into the company’s Parkinson’s disease data, he told Fierce Biotech it “sang” to him. The former internist-turned-biotech CEO knew a thing or two about Parkinson’s—an area Oryon is targeting with an autologous neuron replacement therapy designed to restore dopaminergic function.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Fierce Biotech

Scientists turn pig semen extract into eye drops that kill cancer in mice

Published

on

The human eye is like an immunological fortress, with its ability to exclude unwanted intruders a boon when preventing infection but a burden when trying to deliver vital medicines. Researchers in China have now turned to an unusual source—pig semen—to develop eye drops that can deliver cancer drugs to the back of the eye.

Continue Reading

Fierce Biotech

AstraZeneca’s in vivo CAR-T bet eradicates cancer in 3 of 5 patients, but death mars dataset

Published

on

AstraZeneca isn’t letting a death in a China trial detract from the potential of its $1 billion in vivo bet, even as the candidate’s safety and efficacy profile have so far failed to separate it from traditional CAR-T therapies.

Continue Reading

Fierce Biotech

After local tumor approval, Novocure touts positive data in metastatic pancreatic cancer

Published

on

After collecting an FDA approval earlier this year for local pancreatic cancer, Novocure is putting forward positive clinical data for its electric field-based treatment in metastatic cases of the aggressive disease.

Continue Reading
Advertisement

Trending